Management of translocation carcinomas of the kidney

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Microphthalmia-associated transcription factor family translocation renal cell carcinoma (MiT-tRCC) is a rare kidney cancer subtype characterized by gene fusions involving MiT transcription factors.
• MiT-tRCC, including TFE3-rearranged RCC (Xp11 translocation RCC), is increasingly identified in adults, not just children and young adults.
• This subtype was officially recognized by the WHO in 2004 and recently included as a distinct group of 'molecularly defined renal carcinomas' in the 2022 WHO classification.

Purpose of the Study:

• To provide an overview of translocation renal cell carcinoma (MiT-tRCC).
• To discuss current advancements in the management of MiT-tRCC.
• To highlight the integration of recent therapeutic breakthroughs into MiT-tRCC treatment strategies.

Main Methods:

• Review of current literature on MiT-tRCC.
• Analysis of recent diagnostic and molecular sequencing findings.
• Evaluation of emerging therapeutic options, including immune-checkpoint inhibitors and targeted therapies.

Main Results:

• Enhanced comprehension of MiT-tRCC through advanced diagnostic and molecular sequencing assays.
• Identification of novel and distinct molecular features within this tumor subtype.
• Broadened therapeutic landscape for MiT-tRCC, influenced by advances in clear cell RCC treatment.

Conclusions:

• Recent advancements have significantly improved the understanding of MiT-tRCC.
• Novel therapeutic strategies are being explored and integrated into the management of MiT-tRCC.
• Continued research is crucial for optimizing treatment outcomes for this rare kidney cancer.